Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies

Condition	Treatment or Intervention	Phase
advanced, solid, malignancies	Drug: AZD5438	Phase I

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Advanced solid malignancy
• Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion Criteria:

• Radiotherapy within 3 weeks of the start of treatment
• Investigational product within the last 3 weeks
• Systemic cytotoxic anti-cancer therapy within the last 3 weeks
• Any significant clinical disorder that makes it undesirable for the patient to participate

AstraZeneca Information Center (8a-7P EST)      800-236-9933 

Massachusetts
      Research Site, Boston,  Massachusetts,  United States; Recruiting
New York
      Research Site, New York City,  New York,  United States; Recruiting

Study ID Numbers:  D0110C00005
Record last reviewed:  September 2004
Record first received:  August 4, 2004
ClinicalTrials.gov Identifier:  NCT00088790
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-09